Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of LCP-Tacrolimus Conversion in Kidney Transplant
NCT02961608Phase 4Completed
- Sponsor
- Bellvitge University Hospital
- Start
- May 2016
- Primary completion
- Sep 2018
- Modality
- RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tacrolimus in kidney transplant rejection, sponsored by Bellvitge University Hospital. Primary endpoint: Area under the curve of Calcineurin activity at 35 days. Started May 2016; status: completed.
02
Drugs
tacrolimus
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT02961608.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02961608.